Tiragolumab — Drug Intelligence | 20 EU Trials

Filter these 20 trials by condition, phase, country and more.

Open in Search →

20 Registered trials

3 Recruiting

16 Completed trials

8 Sponsors

13 Countries

Phase III

Phase II

Phase I/II

Phase III: 6 Phase II/III: 1 Phase II: 9 Phase I/II: 3 Phase I (Other): 1

Oversight events:

1 temporary halt 2 unexpected events across 3 trials

View oversight register →

Indications tested

Non-small cell lung cancer metastatic 2 Non-small cell lung cancer 2 Hepatocellular carcinoma 1 Small cell lung cancer 1 Non-small cell lung cancer stage III 1 Triple negative breast cancer 1 Small cell lung cancer extensive stage 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 13 Genentech Inc. 1 Grupo Espanol Multidisciplinar En Cancer Digestivo 1 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting 1 Institut Curie 1 Institut fuer Klinische Krebsforschung IKF GmbH 1 Roche Farma S.A. 1 Universitair Medisch Centrum Groningen 1

All trials

20 total

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Advanced Liver Cancers (M… Recruiting

2023-506611-17-00 Phase I/II 1 country F. Hoffmann-La Roche AG
NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial Recruiting

2023-507875-23-00 Phase II 1 country Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting

2023-504263-16-00 Phase III 4 countries F. Hoffmann-La Roche AG
Tiragolumab and atezolizumab associated with chemotherapy in triple negative breast cancer Ended

2022-501561-51-00 Phase II 1 country Institut Curie
A Study to Evaluate Atezolizumab and Bevacizumab, with and without Tiragolumab, In Patients With Untreated Locally Advanced or Metastatic He… Ended

2023-503422-39-00 Phase III 6 countries F. Hoffmann-La Roche AG
TIRACAN; Open label phase 2 basket trial with Atezolizumab and Tiragolumab in solid tumors Ended

2024-512616-21-00 Phase II 1 country Universitair Medisch Centrum Groningen
Phase II study of Atezolizumab plus Tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal… Ended

2023-509485-38-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated … Ended

2023-504027-78-00 Phase II 7 countries F. Hoffmann-La Roche AG
A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended

2022-502052-30-00 Phase III 9 countries F. Hoffmann-La Roche AG
The NeoTRACK Trial – Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy – Dissection of IO efficacy in NSCLC by longitudinal tracKing: a… Halted

2022-501322-38-00 Phase II 1 country Institut fuer Klinische Krebsforschung IKF GmbH
A PHASE II STUDY OF ADJUVANT ATEZOLIZUMAB OR ATEZOLIZUMAB PLUS TIRAGOLUMAB IN SOLID TUMORS WITH RESECTABLE DISEASE WITH INTERMEDIATE-HIGH RI… Ended

2024-512635-71-00 Phase II 1 country Roche Farma S.A.
A Study Evaluating the Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients with Surgically Resectable Hepatocellular C… Ended

2022-502840-11-00 Phase I/II 4 countries F. Hoffmann-La Roche AG
A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Patients with Recurrent/Metastatic PD-L1 P… Ended

2023-509449-10-00 Phase II 6 countries F. Hoffmann-La Roche AG
A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and C… Ended

2022-502031-20-00 Phase II/III 6 countries F. Hoffmann-La Roche AG
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cel… Ended

2022-502480-38-00 Phase III 11 countries F. Hoffmann-La Roche AG
A Study of Atezolizumab plus Carboplatin and Etoposide with or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Untreated Extensiv… Ended

2022-502988-37-00 Phase III 3 countries F. Hoffmann-La Roche AG
A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended

2022-502482-17-00 Phase III 8 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients with Urothelial Carcinoma… Ended

2024-511316-25-00 Phase I (Other) 3 countries F. Hoffmann-La Roche AG
A Study to Assess Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small … Ended

2023-508083-30-00 Phase II 2 countries Genentech Inc.
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Duc… Ended

2024-511271-15-00 Phase I/II 1 country F. Hoffmann-La Roche AG

Showing 1–20 of 20 trials

← All drugs A–Z